Eustachio Nettis1, Vincenzo Patella2, Carla Lombardo3, Aikaterini Detoraki4, Luigi Macchia1, Elisabetta Di Leo5, Monica Carbonara6, Giorgio W Canonica7, Laura Bonzano8. 1. Department of Emergency and Organ Transplantation, School and Chair of Allergology and Clinical Immunology, University of Bari - Aldo Moro, Bari, Italy. 2. Division of Allergy and Clinical Immunology, Department of Medicine ASL Salerno, Santa Maria della Speranza" Hospital, Salerno, Italy. 3. Division of Dermatology "U.O. Multizonale APSS", Santa Chiara Hospital, Trento, Italy. 4. Department of Internal Medicine and Clinical Pathology, Azienda Ospedaliera Universitaria Federico II, Naples, Italy. 5. Section of Allergy and Clinical Immunology, Unit of Internal Medicine-"F. Miulli" Hospital, Acquaviva delle Fonti, Bari, Italy. 6. National Institute of Statistics (ISTAT), Bari, Italy. 7. Humanitas University Head Personalized Medicine Asthma & Allergy Clinic-Humanitas Research Hospital-IRCCS, Milano, Italy. 8. Dermatology Unit, Surgical, Medical and Dental Department of Morphological Sciences Related to Transplant, Oncology and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Italy.
Abstract
BACKGROUND: Dupilumab is an anti-IL-4Rα antibody used in the treatment of patients with moderate-to-severe atopic dermatitis (msAD). This study explored the potential benefit of dupilumab in perennial allergic rhinoconjunctivitis (PAR) and perennial allergic asthma (PAA) caused by indoor allergens in adults with msAD. METHODS: This multicentric, prospective, observational, real-life study included adult patients with msAD who had been treated with dupilumab in 16 Italian care centres. Efficacy outcomes regarding AD, PAR and PAA were collected at baseline and 16 weeks. Safety was also assessed. RESULTS: We enrolled 123 patients with msAD. Between baseline and 16 weeks of treatment, the following measurements decreased statistically significantly: Eczema Area and Severity Index, SCOring AD, Patient-Oriented Eczema Measure, pruritus score, sleep score, Dermatology Life Quality Index and IgE. Dupilumab treatment in patients with comorbid PAR (n = 41) was associated with significant improvements in PAR disease control (measured using a Rhinitis Control Scoring System) and in PAR Quality of life (QoL) (measured using the Rhinoconjunctivitis QoL Questionnaire scores). In 32 patients with comorbid PAA, dupilumab significantly improved PAA control (measured using the Asthma Control Test and five-item Asthma Control Questionnaire scores) and disease-related QoL (measured using the Asthma QoL Questionnaire scores). Thirty-five patients (28.5%) developed conjunctivitis during the study period. CONCLUSION: These results support the benefits of dupilumab for adult patients with PAR and/or PAA associated with msAD.
BACKGROUND:Dupilumab is an anti-IL-4Rα antibody used in the treatment of patients with moderate-to-severe atopic dermatitis (msAD). This study explored the potential benefit of dupilumab in perennial allergic rhinoconjunctivitis (PAR) and perennial allergic asthma (PAA) caused by indoor allergens in adults with msAD. METHODS: This multicentric, prospective, observational, real-life study included adult patients with msAD who had been treated with dupilumab in 16 Italian care centres. Efficacy outcomes regarding AD, PAR and PAA were collected at baseline and 16 weeks. Safety was also assessed. RESULTS: We enrolled 123 patients with msAD. Between baseline and 16 weeks of treatment, the following measurements decreased statistically significantly: Eczema Area and Severity Index, SCOring AD, Patient-Oriented Eczema Measure, pruritus score, sleep score, Dermatology Life Quality Index and IgE. Dupilumab treatment in patients with comorbid PAR (n = 41) was associated with significant improvements in PAR disease control (measured using a Rhinitis Control Scoring System) and in PAR Quality of life (QoL) (measured using the Rhinoconjunctivitis QoL Questionnaire scores). In 32 patients with comorbid PAA, dupilumab significantly improved PAA control (measured using the Asthma Control Test and five-item Asthma Control Questionnaire scores) and disease-related QoL (measured using the Asthma QoL Questionnaire scores). Thirty-five patients (28.5%) developed conjunctivitis during the study period. CONCLUSION: These results support the benefits of dupilumab for adult patients with PAR and/or PAA associated with msAD.
Authors: Eustachio Nettis; Luisa Brussino; Vincenzo Patella; Laura Bonzano; Aikaterini Detoraki; Elisabetta Di Leo; Maria Maddalena Sirufo; Cristiano Caruso; Fabio Lodi Rizzini; Mariaelisabetta Conte; Mona-Rita Yacoub; Massimo Triggiani; Erminia Ridolo; Luigi Macchia; Giovanni Rolla; Raffaele Brancaccio; Amato De Paulis; Giuseppe Spadaro; Danilo Di Bona; Angela Maria D'Uggento; Lia Ginaldi; Francesco Gaeta; Eleonora Nucera; Kliljeda Jaubashi; Danilo Villalta; Lorenzo Dagna; Domenico Ciotta; Francesco Pucciarini; Diego Bagnasco; Giorgio Celi; Fulvia Chieco Bianchi; Lorenzo Cosmi; Maria Teresa Costantino; Maria Angiola Crivellaro; Simona D'Alò; Pietro Del Biondo; Stefano Del Giacco; Mario Di Gioacchino; Linda Di Pietro; Elisabetta Favero; Sebastiano Gangemi; Gabriella Guarnieri; Enrico Heffler; Maria Stefania Leto Barone; Carla Lombardo; Francesca Losa; Andrea Matucci; Paola Lucia Minciullo; Paola Parronchi; Giovanni Passalacqua; Stefano Pucci; Oliviero Rossi; Lorenzo Salvati; Michele Schiappoli; Gianenrico Senna; Andrea Vianello; Alessandra Vultaggio; Yang Baoran; Cristoforo Incorvaia; Giorgio Walter Canonica Journal: Clin Mol Allergy Date: 2022-05-19
Authors: Jonathan Corren; Sarbjit S Saini; Remi Gagnon; Mark H Moss; Gordon Sussman; Joshua Jacobs; Elizabeth Laws; Elinore S Chung; Tatiana Constant; Yiping Sun; Jennifer Maloney; Jennifer D Hamilton; Marcella Ruddy; Claire Q Wang; Meagan P O'Brien Journal: J Asthma Allergy Date: 2021-08-16